minocycline

Interventions targeting astrocyte phenotypes, including minocycline and Lcn2 knockdown, normalized the posterior piriform cortex neurochemistry and alleviated both nociceptive and affective symptoms. These findings define a mechanistic framework in which astrocytic dysfunction orchestrates pain and depression, and highlight astrocyte-directed strategies for treating cancer pain-depression comorbidity.

P=N/A, N=80, Not yet recruiting, The First Affiliated Hospital of Xinxiang Medical College

Interventions to correct glial dysfunction-e.g., anti-inflammatory medication (e.g., minocycline, ibudilast), gene therapy, and stem cell therapy-are investigated for their potential to restore glia to normal and diminish ASD symptoms. Understanding glial-neuronal communication mechanisms and their role in neuroinflammation offers a hopeful future for accurate, target-specific treatment. Advances in the elucidation of these processes will foretell an enormous increase in therapeutic efficacy and quality of life for individuals with ASD.

P1, N=30, Not yet recruiting, University of Cincinnati | Trial completion date: Dec 2026 --> Jun 2028 | Trial primary completion date: May 2026 --> Dec 2027

P2, N=305, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting

Furthermore, intraperitoneal injection of minocycline (40 mg/kg) with ACR reduced the levels of MDA, IL-1β, and caspase-3-cleaved proteins in the cerebral cortex. Administration of minocycline exhibits both prophylactic and therapeutic properties against ACR-induced neurotoxicity primarily through anti-oxidant, anti-apoptotic, and anti-inflammatory properties.

This study aimed to investigate the anticancer potential of three tetracycline analogues chemically modified tetracycline-3 (COL-3), doxycycline (DOX), and minocycline (MIN) in leukemia models, with a particular focus on their cytotoxic effects and modulation of the JAK2/STAT3 signaling pathway. Among them, COL-3 emerges as the most potent analogue and acts through both JAK/STAT-dependent and -independent mechanisms. This work supports further investigation of COL-3 as a candidate for drug repurposing strategies in hematological malignancies.

Furthermore, the anxiety-like behaviors in NSUN5-deficient mice were also relieved by rmFGF2 or minocycline treatments. Taken together, our study unveils a previously unknown effect of NSUN5 on anxiety disorders and a role of NSUN5 in regulating OPCs-microglia interaction and synaptic plasticity of BLA.

P3, N=1192, Recruiting, Beijing Tiantan Hospital | Not yet recruiting --> Recruiting | Initiation date: Jan 2026 --> Apr 2026

P4, N=42, Not yet recruiting, Stony Brook University | Trial completion date: Jan 2031 --> Jan 2032 | Trial primary completion date: Jun 2030 --> Jun 2031

P=N/A, N=52, Completed, The Fifth Affiliated Hospital of Guangzhou Medical University; The Fifth Affiliated Hospital of Guangzhou Medical University

P=N/A, N=624, Peking University Third Hospital; Peking University Third Hospital